LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using ...
Accelerate CGT developement with strategic viral vector manufacturing and CDMO partnerships that balance quality, cost, and speed from bench to clinic.
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or ...
BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...
Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture replacement organs and cellular therapies. Many groups have shown therapeutic ...
Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (PRRUF) (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results